AI-Driven Drug Discovery to Address Antimicrobial Resistance and Glioblastoma: Stoked Bio's MOSAIC Platform Approach

Thursday, September 25, 2025 at 8 AM (PT) | 11 AM (ET) | 4 PM (BST) | 5 PM (CEST)

Reserve Your Webinar Seat

Stoked Bio is on a mission to transform how we discover medicines for the world's most intractable diseases, including drug-resistant infections and glioblastoma, a deadly form of brain cancer.

Founded by Dr. Jon Stokes, whose academic lab pioneered the use of AI for antibiotic discovery, Stoked Bio is now applying its biology-first, AI-assisted platform---MOSAIC---to identify novel small molecules that work where conventional drug discovery has failed.

In this webinar, Dr. Stokes will join Collaborative Drug Discovery (CDD) to explore:

Why antimicrobial resistance (AMR) and glioblastoma represent urgent and overlooked therapeutic frontiers
How the MOSAIC platform integrates deep learning and wet-lab biology to overcome resistance mechanisms in both infectious diseases and cancer
Stoked Bio's approach to antibiotic development and the economic and regulatory challenges preventing AI/ML companies from pursuing these critical but commercially difficult targets
The scientific rationale and development process behind Stoked Bio's leading candidates for recurrent glioblastoma
How CDD Vault supports Stoked Bio's collaborative R&D model across disciplines and partners, ensuring data integrity across diverse therapeutic programs
Lessons from bridging the gap between academic discovery and biotech commercialization in high-risk, high-need therapeutic areas

Whether you're a drug discovery scientist, biotech founder, or translational researcher, this session offers a behind-the-scenes look at how cutting-edge science, structured data, and AI are reshaping the drug development pipeline for diseases that traditional pharma approaches have failed to address.

Reserve your spot today!

Jon Stokes, PhD

Co-founder and CSO of Stoked Bio and Assistant Professor at McMaster University

Dr. Jon Stokes is the Co-founder and CSO of Stoked Bio and Assistant Professor at McMaster University, focusing on AI-driven drug discovery for challenging infectious diseases and cancers. In his academic role, he develops and applies artificial intelligence methods to discover novel antibiotics and advances computational approaches to understand bacterial cell physiology in complex infection settings. He has extensive experience in machine learning applications for antibiotic discovery and has contributed to breakthrough research in antimicrobial resistance solutions. Dr. Stokes completed his PhD and postdoctoral training in microbiology, chemical biology, and artificial intelligence. He is recognized for his pioneering work in leveraging AI for drug discovery, particularly in developing next-generation antibiotics with expanded capabilities over current state-of-the-art treatments.

Jeff Skinner, MBA

CEO of Stoked Bio

Jeff Skinner is CEO of Stoked Bio, where he leads business development, licensing, and strategic partnerships to advance next-generation therapeutics. He has extensive experience in the pharmaceutical and biotech sectors, spanning early discovery through clinical and commercial development. Over his career, he has successfully completed global licensing agreements, managed research collaborations, and built partnerships that have accelerated drug development pipelines.

Previously, Mr. Skinner was Vice President of Business Development at Valeo Pharma, where he expanded a portfolio of branded therapeutics in respiratory, ophthalmology, and hospital products. He also held senior business development roles at Stemtrix Inc. and advised pharmaceutical companies including Antis Pharma and Ortho RTi on growth strategy, licensing, and deal execution.

Mr. Skinner earned a BSc in Genetics and an MBA from Western University. He is recognized for his ability to identify and secure strategic alliances, negotiate complex licensing deals, and guide emerging biopharma companies through critical stages of growth and commercialization.

James White, PhD

Collaborative Communications at CDD Vault

James White is Director of Collaborative Communications at Collaborative Drug Discovery (CDD Vault), focusing on scientific communication and digital media solutions for biotechnology research organizations. Previously, he served as Associate at Ropes & Gray and Project Manager at Hera Health Solutions, where he developed venture capital networking platforms and provided support for defense grant applications. He completed his PhD in Cell and Developmental Biology at Vanderbilt University and holds a BS in Biopsychology, Cognition, and Neuroscience from the University of Michigan. Dr. White has extensive experience in strategic business development, project management, and fostering partnerships within startup ecosystems, with expertise in communicating complex scientific research to diverse audiences.